Effects of activation of the farnesoid X receptor (FXR) on hepatic lipid and glucose metabolism in patients with the metabolic syndrome and familial forms of hypertriglyceridemia.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Chenodeoxycholic acid (Primary)
- Indications Hyperlipidaemia; Hyperlipoproteinaemia type IV; Metabolic syndrome
- Focus Pharmacodynamics
- 09 Mar 2012 Biomarkers information updated
- 08 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Nov 2007 The expected completion date for this trial is now 1 Feb 2008.